Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oscar Health, Inc.OSCR · Entity 3582 | Director · Co-Founder and Vice Chairman · 10% owner | November 20, 2024 | November 22, 2024 |
| Vimeo, Inc.VMEO · Entity 72624 | Director | May 25, 2021 | May 27, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oscar Health, Inc.
Report date November 20, 2024 · Filed November 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 6,243,617 |
Reported balance
After 2024-11-20 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-11-20 · Purchase · Acquired 88,395 · Balance 6,243,617 F1: Represents (i) 87,343 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,052 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.92 to $17.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,169,288 shares are held directly by Thrive VII Growth and 74,329 shares are held directly by Claremount VII. F2: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 6,343,617 |
Reported balance
After 2024-11-21 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-11-21 · Purchase · Acquired 100,000 · Balance 6,343,617 F3: Represents (i) 98,809 shares purchased by Thrive VII Growth and (ii) 1,191 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.60 to $17.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,268,097 shares are held directly by Thrive VII Growth and 75,520 shares are held directly by Claremount VII. F2: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents (i) 87,343 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,052 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.92 to $17.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,169,288 shares are held directly by Thrive VII Growth and 74,329 shares are held directly by Claremount VII.
F2: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.
F3: Represents (i) 98,809 shares purchased by Thrive VII Growth and (ii) 1,191 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.60 to $17.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,268,097 shares are held directly by Thrive VII Growth and 75,520 shares are held directly by Claremount VII.
Vimeo, Inc.
Report date May 25, 2021 · Filed May 27, 2021
Jointly reported with Thrive Partners V GP, LLC, Thrive Partners VI GP, LLC, Thrive Capital Partners V, L.P., Claremount V Associates, L.P., Thrive Capital Partners VI, L.P., Thrive Capital Partners VI Growth, L.P., Claremount VI Associates, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Claremount V Associates, L.P. | 30,809 |
Reported balance
After 2021-05-25 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-05-25 · Grant · Acquired 30,809 · Balance 30,809 F1: Shares acquired in connection with the spin-off of the Issuer from IAC/InterActiveCorp ("IAC") that was completed on May 25, 2021, pursuant to which each share of Vimeo.com, Inc., formerly known as Vimeo, Inc. ("Vimeo"), capital stock issued and outstanding immediately prior to the completion of the spin-off and owned by a non-IAC Vimeo stockholder (other than any dissenting shares) was automatically cancelled and converted into 1.0143 shares of the Issuer's common stock. F2: Shares held by Claremount V Associates, L.P. ("Claremount V"). F7: The general partner of each of Thrive V and Claremount V is Thrive Partners V GP, LLC ("Thrive V GP"). The general partner of each of Thrive VI, Thrive VI Growth and Claremount VI is Thrive Partners VI GP, LLC ("Thrive VI GP" and together with Thrive V GP, the "Thrive General Partners"). Joshua Kushner is the sole managing member of each of the Thrive General Partners, and, in his capacity as managing member, may have voting and investment power over the shares held by each of the Thrive Capital Funds. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive Capital Funds except to the extent of their pecuniary interest therein. F8: Nabil Mallick, a General Partner at Thrive Capital, has been deputized to represent the reporting persons on the board of directors of the Issuer. By virtue of Mr. Mallick's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the reporting persons may be deemed directors by deputization of the Issuer. Mr. Mallick has filed a separate Section 16 report disclosing securities of the Issuer that he may be deemed to beneficially own for Section 16 purposes. |
| Common StockSEC Table I · non-derivative | IndirectBy Claremount VI Associates, L.P. | 79,902 |
Reported balance
After 2021-05-25 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-05-25 · Grant · Acquired 79,902 · Balance 79,902 F1: Shares acquired in connection with the spin-off of the Issuer from IAC/InterActiveCorp ("IAC") that was completed on May 25, 2021, pursuant to which each share of Vimeo.com, Inc., formerly known as Vimeo, Inc. ("Vimeo"), capital stock issued and outstanding immediately prior to the completion of the spin-off and owned by a non-IAC Vimeo stockholder (other than any dissenting shares) was automatically cancelled and converted into 1.0143 shares of the Issuer's common stock. F3: Shares held by Claremount VI Associates, L.P. ("Claremount VI"). F7: The general partner of each of Thrive V and Claremount V is Thrive Partners V GP, LLC ("Thrive V GP"). The general partner of each of Thrive VI, Thrive VI Growth and Claremount VI is Thrive Partners VI GP, LLC ("Thrive VI GP" and together with Thrive V GP, the "Thrive General Partners"). Joshua Kushner is the sole managing member of each of the Thrive General Partners, and, in his capacity as managing member, may have voting and investment power over the shares held by each of the Thrive Capital Funds. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive Capital Funds except to the extent of their pecuniary interest therein. F8: Nabil Mallick, a General Partner at Thrive Capital, has been deputized to represent the reporting persons on the board of directors of the Issuer. By virtue of Mr. Mallick's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the reporting persons may be deemed directors by deputization of the Issuer. Mr. Mallick has filed a separate Section 16 report disclosing securities of the Issuer that he may be deemed to beneficially own for Section 16 purposes. |
| Common StockSEC Table I · non-derivative | IndirectBy Thrive Capital Partners V, L.P. | 1,666,518 |
Reported balance
After 2021-05-25 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2021-05-25 · Grant · Acquired 1,666,518 · Balance 1,666,518 F1: Shares acquired in connection with the spin-off of the Issuer from IAC/InterActiveCorp ("IAC") that was completed on May 25, 2021, pursuant to which each share of Vimeo.com, Inc., formerly known as Vimeo, Inc. ("Vimeo"), capital stock issued and outstanding immediately prior to the completion of the spin-off and owned by a non-IAC Vimeo stockholder (other than any dissenting shares) was automatically cancelled and converted into 1.0143 shares of the Issuer's common stock. F4: Shares held by Thrive Capital Partners V, L.P. ("Thrive V"). F7: The general partner of each of Thrive V and Claremount V is Thrive Partners V GP, LLC ("Thrive V GP"). The general partner of each of Thrive VI, Thrive VI Growth and Claremount VI is Thrive Partners VI GP, LLC ("Thrive VI GP" and together with Thrive V GP, the "Thrive General Partners"). Joshua Kushner is the sole managing member of each of the Thrive General Partners, and, in his capacity as managing member, may have voting and investment power over the shares held by each of the Thrive Capital Funds. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive Capital Funds except to the extent of their pecuniary interest therein. F8: Nabil Mallick, a General Partner at Thrive Capital, has been deputized to represent the reporting persons on the board of directors of the Issuer. By virtue of Mr. Mallick's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the reporting persons may be deemed directors by deputization of the Issuer. Mr. Mallick has filed a separate Section 16 report disclosing securities of the Issuer that he may be deemed to beneficially own for Section 16 purposes. |
| Common StockSEC Table I · non-derivative | IndirectBy Thrive Capital Partners VI, L.P. | 2,525,739 |
Reported balance
After 2021-05-25 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-05-25 · Grant · Acquired 2,525,739 · Balance 2,525,739 F1: Shares acquired in connection with the spin-off of the Issuer from IAC/InterActiveCorp ("IAC") that was completed on May 25, 2021, pursuant to which each share of Vimeo.com, Inc., formerly known as Vimeo, Inc. ("Vimeo"), capital stock issued and outstanding immediately prior to the completion of the spin-off and owned by a non-IAC Vimeo stockholder (other than any dissenting shares) was automatically cancelled and converted into 1.0143 shares of the Issuer's common stock. F5: Shares held by Thrive Capital Partners VI, L.P. ("Thrive VI"). F7: The general partner of each of Thrive V and Claremount V is Thrive Partners V GP, LLC ("Thrive V GP"). The general partner of each of Thrive VI, Thrive VI Growth and Claremount VI is Thrive Partners VI GP, LLC ("Thrive VI GP" and together with Thrive V GP, the "Thrive General Partners"). Joshua Kushner is the sole managing member of each of the Thrive General Partners, and, in his capacity as managing member, may have voting and investment power over the shares held by each of the Thrive Capital Funds. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive Capital Funds except to the extent of their pecuniary interest therein. F8: Nabil Mallick, a General Partner at Thrive Capital, has been deputized to represent the reporting persons on the board of directors of the Issuer. By virtue of Mr. Mallick's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the reporting persons may be deemed directors by deputization of the Issuer. Mr. Mallick has filed a separate Section 16 report disclosing securities of the Issuer that he may be deemed to beneficially own for Section 16 purposes. |
| Common StockSEC Table I · non-derivative | IndirectBy Thrive Capital Partners VI Growth, L.P. | 1,549,885 |
Reported balance
After 2021-05-25 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2021-05-25 · Grant · Acquired 1,549,885 · Balance 1,549,885 F1: Shares acquired in connection with the spin-off of the Issuer from IAC/InterActiveCorp ("IAC") that was completed on May 25, 2021, pursuant to which each share of Vimeo.com, Inc., formerly known as Vimeo, Inc. ("Vimeo"), capital stock issued and outstanding immediately prior to the completion of the spin-off and owned by a non-IAC Vimeo stockholder (other than any dissenting shares) was automatically cancelled and converted into 1.0143 shares of the Issuer's common stock. F6: Shares held by Thrive Capital Partners VI Growth, L.P. ("Thrive VI Growth" and together with Claremount V, Claremount VI, Thrive V and Thrive VI, the "Thrive Capital Funds"). F7: The general partner of each of Thrive V and Claremount V is Thrive Partners V GP, LLC ("Thrive V GP"). The general partner of each of Thrive VI, Thrive VI Growth and Claremount VI is Thrive Partners VI GP, LLC ("Thrive VI GP" and together with Thrive V GP, the "Thrive General Partners"). Joshua Kushner is the sole managing member of each of the Thrive General Partners, and, in his capacity as managing member, may have voting and investment power over the shares held by each of the Thrive Capital Funds. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive Capital Funds except to the extent of their pecuniary interest therein. F8: Nabil Mallick, a General Partner at Thrive Capital, has been deputized to represent the reporting persons on the board of directors of the Issuer. By virtue of Mr. Mallick's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the reporting persons may be deemed directors by deputization of the Issuer. Mr. Mallick has filed a separate Section 16 report disclosing securities of the Issuer that he may be deemed to beneficially own for Section 16 purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired in connection with the spin-off of the Issuer from IAC/InterActiveCorp ("IAC") that was completed on May 25, 2021, pursuant to which each share of Vimeo.com, Inc., formerly known as Vimeo, Inc. ("Vimeo"), capital stock issued and outstanding immediately prior to the completion of the spin-off and owned by a non-IAC Vimeo stockholder (other than any dissenting shares) was automatically cancelled and converted into 1.0143 shares of the Issuer's common stock.
F2: Shares held by Claremount V Associates, L.P. ("Claremount V").
F3: Shares held by Claremount VI Associates, L.P. ("Claremount VI").
F4: Shares held by Thrive Capital Partners V, L.P. ("Thrive V").
F5: Shares held by Thrive Capital Partners VI, L.P. ("Thrive VI").
F6: Shares held by Thrive Capital Partners VI Growth, L.P. ("Thrive VI Growth" and together with Claremount V, Claremount VI, Thrive V and Thrive VI, the "Thrive Capital Funds").
F7: The general partner of each of Thrive V and Claremount V is Thrive Partners V GP, LLC ("Thrive V GP"). The general partner of each of Thrive VI, Thrive VI Growth and Claremount VI is Thrive Partners VI GP, LLC ("Thrive VI GP" and together with Thrive V GP, the "Thrive General Partners"). Joshua Kushner is the sole managing member of each of the Thrive General Partners, and, in his capacity as managing member, may have voting and investment power over the shares held by each of the Thrive Capital Funds. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive Capital Funds except to the extent of their pecuniary interest therein.
F8: Nabil Mallick, a General Partner at Thrive Capital, has been deputized to represent the reporting persons on the board of directors of the Issuer. By virtue of Mr. Mallick's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the reporting persons may be deemed directors by deputization of the Issuer. Mr. Mallick has filed a separate Section 16 report disclosing securities of the Issuer that he may be deemed to beneficially own for Section 16 purposes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 21, 2024 Filed Nov 22, 2024 21:29 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 100,000 | $16.86 | $1,685,980.00 |
DisclosureSEC source: 0000950170-24-130229 · ownership.xml · nonDerivative · entry 2 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 6,343,617 F3 · shares: Represents (i) 98,809 shares purchased by Thrive VII Growth and (ii) 1,191 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.60 to $17.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,268,097 shares are held directly by Thrive VII Growth and 75,520 shares are held directly by Claremount VII. F3 · price: Represents (i) 98,809 shares purchased by Thrive VII Growth and (ii) 1,191 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.60 to $17.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,268,097 shares are held directly by Thrive VII Growth and 75,520 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 98,809 shares purchased by Thrive VII Growth and (ii) 1,191 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.60 to $17.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,268,097 shares are held directly by Thrive VII Growth and 75,520 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:29 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 88,395 | $16.97 | $1,499,700.73 |
DisclosureSEC source: 0000950170-24-130229 · ownership.xml · nonDerivative · entry 1 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 6,243,617 F1 · shares: Represents (i) 87,343 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,052 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.92 to $17.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,169,288 shares are held directly by Thrive VII Growth and 74,329 shares are held directly by Claremount VII. F1 · price: Represents (i) 87,343 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,052 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.92 to $17.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,169,288 shares are held directly by Thrive VII Growth and 74,329 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 87,343 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,052 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.92 to $17.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,169,288 shares are held directly by Thrive VII Growth and 74,329 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 21:55 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 185,790 | $15.97 | $2,966,155.93 |
DisclosureSEC source: 0000950170-24-128056 · ownership.xml · nonDerivative · entry 2 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 6,155,222 F3 · shares: Represents (i) 183,567 shares purchased by Thrive VII Growth and (ii) 2,223 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.87 to $16.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,081,945 shares are held directly by Thrive VII Growth and 73,277 shares are held directly by Claremount VII. F3 · price: Represents (i) 183,567 shares purchased by Thrive VII Growth and (ii) 2,223 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.87 to $16.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,081,945 shares are held directly by Thrive VII Growth and 73,277 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 183,567 shares purchased by Thrive VII Growth and (ii) 2,223 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.87 to $16.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,081,945 shares are held directly by Thrive VII Growth and 73,277 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 21:55 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 158,732 | $15.61 | $2,478,187.48 |
DisclosureSEC source: 0000950170-24-128056 · ownership.xml · nonDerivative · entry 1 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,969,432 F1 · shares: Represents (i) 156,855 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,877 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.87 to $15.865, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,898,378 shares are held directly by Thrive VII Growth and 71,054 shares are held directly by Claremount VII. F1 · price: Represents (i) 156,855 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,877 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.87 to $15.865, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,898,378 shares are held directly by Thrive VII Growth and 71,054 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 156,855 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,877 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.87 to $15.865, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,898,378 shares are held directly by Thrive VII Growth and 71,054 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| November 13, 2024 Filed Nov 14, 2024 02:13 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 358,619 | $13.74 | $4,926,313.34 |
DisclosureSEC source: 0000950170-24-126664 · ownership.xml · nonDerivative · entry 3 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,810,700 F4 · shares: Represents (i) 354,349 shares purchased by Thrive VII Growth and (ii) 4,270 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.435 to $14.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,741,523 shares are held directly by Thrive VII Growth and 69,177 shares are held directly by Claremount VII. F4 · price: Represents (i) 354,349 shares purchased by Thrive VII Growth and (ii) 4,270 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.435 to $14.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,741,523 shares are held directly by Thrive VII Growth and 69,177 shares are held directly by Claremount VII. F4 · balance_after: Represents (i) 354,349 shares purchased by Thrive VII Growth and (ii) 4,270 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.435 to $14.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,741,523 shares are held directly by Thrive VII Growth and 69,177 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 02:13 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 420,819 | $13.68 | $5,755,625.63 |
DisclosureSEC source: 0000950170-24-126664 · ownership.xml · nonDerivative · entry 2 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,452,081 F3 · shares: Represents (i) 415,808 shares purchased by Thrive VII Growth and (ii) 5,011 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.45 to $14.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,387,174 shares are held directly by Thrive VII Growth and 64,907 shares are held directly by Claremount VII. F3 · price: Represents (i) 415,808 shares purchased by Thrive VII Growth and (ii) 5,011 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.45 to $14.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,387,174 shares are held directly by Thrive VII Growth and 64,907 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 415,808 shares purchased by Thrive VII Growth and (ii) 5,011 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.45 to $14.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,387,174 shares are held directly by Thrive VII Growth and 64,907 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 02:13 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 276,040 | $13.58 | $3,748,043.52 |
DisclosureSEC source: 0000950170-24-126664 · ownership.xml · nonDerivative · entry 1 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,031,262 F1 · shares: Represents (i) 272,754 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,286 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.205 to $13.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,971,366 shares are held directly by Thrive VII Growth and 59,896 shares are held directly by Claremount VII. F1 · price: Represents (i) 272,754 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,286 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.205 to $13.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,971,366 shares are held directly by Thrive VII Growth and 59,896 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 272,754 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,286 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.205 to $13.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,971,366 shares are held directly by Thrive VII Growth and 59,896 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 21:05 UTC | Oscar Health, Inc. OSCR · Entity 3582 | Grant7.25% Convertible Senior Notes · Derivative | 417,000 | $417,000.00 Strike: $8.32 | $173,889,000,000.00 |
DisclosureSEC source: 0000899243-22-005008 · doc4.xml · derivative · entry 2 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Claremount VII Associates, L.P. Disclosed balance after: 417,000 Underlying: Class A Common Stock · 50,111 shares Expires not disclosed F1 · derivative.exercise_date: The 7.25% Convertible Senior Notes (the "Notes") are governed by an indenture (the "Indenture") between the Issuer and U.S. Bank National Association, as trustee (the "Trustee"). The Notes bear interest at a rate of 7.25% per annum, payable in cash, commencing on June 30, 2022. The Notes may be converted by the holder, subject to certain conditions, at an initial conversion price of approximately $8.32. Before August 31, 2031, holders of the Notes have the right to convert their Notes only upon the occurrence of certain events more fully described in the Indenture. From and after August 31, 2031, holders of the Notes may convert their Notes at any time at their election until the close of business on the second scheduled trading day immediately before the December 31, 2031 maturity date. Upon conversion, the Notes will be settled, at the Issuer's election, in shares of Class A Common Stock, cash, or a combination of cash and shares of Class A Common Stock, F2 · derivative.exercise_date: (Continued from Footnote 1) subject to certain exceptions, including the right of the holder to elect to settle the Notes by Physical Settlement (as defined in the Indenture) upon conversion pursuant to the terms of the Investment Agreement, dated January 27, 2022, between the Issuer and the purchasers of the Notes. The conversion rate and conversion price are subject to customary adjustments upon the occurrence of certain events. Holders of the Notes have the right to require the Issuer to repurchase all or some of their Notes for cash, subject to certain conditions. The Notes are also subject to redemption under certain circumstances and include customary provisions relating to the occurrence of "Events of Default" (as defined in the Indenture). The Notes have a stated maturity of December 31, 2031, subject to earlier conversion, redemption or repurchase in accordance with their terms. F1 · derivative.expiration_date: The 7.25% Convertible Senior Notes (the "Notes") are governed by an indenture (the "Indenture") between the Issuer and U.S. Bank National Association, as trustee (the "Trustee"). The Notes bear interest at a rate of 7.25% per annum, payable in cash, commencing on June 30, 2022. The Notes may be converted by the holder, subject to certain conditions, at an initial conversion price of approximately $8.32. Before August 31, 2031, holders of the Notes have the right to convert their Notes only upon the occurrence of certain events more fully described in the Indenture. From and after August 31, 2031, holders of the Notes may convert their Notes at any time at their election until the close of business on the second scheduled trading day immediately before the December 31, 2031 maturity date. Upon conversion, the Notes will be settled, at the Issuer's election, in shares of Class A Common Stock, cash, or a combination of cash and shares of Class A Common Stock, F2 · derivative.expiration_date: (Continued from Footnote 1) subject to certain exceptions, including the right of the holder to elect to settle the Notes by Physical Settlement (as defined in the Indenture) upon conversion pursuant to the terms of the Investment Agreement, dated January 27, 2022, between the Issuer and the purchasers of the Notes. The conversion rate and conversion price are subject to customary adjustments upon the occurrence of certain events. Holders of the Notes have the right to require the Issuer to repurchase all or some of their Notes for cash, subject to certain conditions. The Notes are also subject to redemption under certain circumstances and include customary provisions relating to the occurrence of "Events of Default" (as defined in the Indenture). The Notes have a stated maturity of December 31, 2031, subject to earlier conversion, redemption or repurchase in accordance with their terms. F4 · ownership.nature: Securities held directly by Claremount VII Associates, L.P. ("Claremount VII"). Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the securities held by Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 21:05 UTC | Oscar Health, Inc. OSCR · Entity 3582 | Grant7.25% Convertible Senior Notes · Derivative | 34,583,000 | $34,583,000.00 Strike: $8.32 | $1,195,983,889,000,000.00 |
DisclosureSEC source: 0000899243-22-005008 · doc4.xml · derivative · entry 1 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Thrive Capital Partners VII Growth, L.P. Disclosed balance after: 34,583,000 Underlying: Class A Common Stock · 4,155,911 shares Expires not disclosed F1 · derivative.exercise_date: The 7.25% Convertible Senior Notes (the "Notes") are governed by an indenture (the "Indenture") between the Issuer and U.S. Bank National Association, as trustee (the "Trustee"). The Notes bear interest at a rate of 7.25% per annum, payable in cash, commencing on June 30, 2022. The Notes may be converted by the holder, subject to certain conditions, at an initial conversion price of approximately $8.32. Before August 31, 2031, holders of the Notes have the right to convert their Notes only upon the occurrence of certain events more fully described in the Indenture. From and after August 31, 2031, holders of the Notes may convert their Notes at any time at their election until the close of business on the second scheduled trading day immediately before the December 31, 2031 maturity date. Upon conversion, the Notes will be settled, at the Issuer's election, in shares of Class A Common Stock, cash, or a combination of cash and shares of Class A Common Stock, F2 · derivative.exercise_date: (Continued from Footnote 1) subject to certain exceptions, including the right of the holder to elect to settle the Notes by Physical Settlement (as defined in the Indenture) upon conversion pursuant to the terms of the Investment Agreement, dated January 27, 2022, between the Issuer and the purchasers of the Notes. The conversion rate and conversion price are subject to customary adjustments upon the occurrence of certain events. Holders of the Notes have the right to require the Issuer to repurchase all or some of their Notes for cash, subject to certain conditions. The Notes are also subject to redemption under certain circumstances and include customary provisions relating to the occurrence of "Events of Default" (as defined in the Indenture). The Notes have a stated maturity of December 31, 2031, subject to earlier conversion, redemption or repurchase in accordance with their terms. F1 · derivative.expiration_date: The 7.25% Convertible Senior Notes (the "Notes") are governed by an indenture (the "Indenture") between the Issuer and U.S. Bank National Association, as trustee (the "Trustee"). The Notes bear interest at a rate of 7.25% per annum, payable in cash, commencing on June 30, 2022. The Notes may be converted by the holder, subject to certain conditions, at an initial conversion price of approximately $8.32. Before August 31, 2031, holders of the Notes have the right to convert their Notes only upon the occurrence of certain events more fully described in the Indenture. From and after August 31, 2031, holders of the Notes may convert their Notes at any time at their election until the close of business on the second scheduled trading day immediately before the December 31, 2031 maturity date. Upon conversion, the Notes will be settled, at the Issuer's election, in shares of Class A Common Stock, cash, or a combination of cash and shares of Class A Common Stock, F2 · derivative.expiration_date: (Continued from Footnote 1) subject to certain exceptions, including the right of the holder to elect to settle the Notes by Physical Settlement (as defined in the Indenture) upon conversion pursuant to the terms of the Investment Agreement, dated January 27, 2022, between the Issuer and the purchasers of the Notes. The conversion rate and conversion price are subject to customary adjustments upon the occurrence of certain events. Holders of the Notes have the right to require the Issuer to repurchase all or some of their Notes for cash, subject to certain conditions. The Notes are also subject to redemption under certain circumstances and include customary provisions relating to the occurrence of "Events of Default" (as defined in the Indenture). The Notes have a stated maturity of December 31, 2031, subject to earlier conversion, redemption or repurchase in accordance with their terms. F3 · ownership.nature: Securities held directly by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth"). Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Joshua Kushner is the sole managing member of Thrive Partners VII Growth and, in his capacity as managing member, has voting and investment power over the securities held by Thrive VII Growth. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth except to the extent of their pecuniary interest therein. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 21:38 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 323,725 | $17.86 | $5,780,109.88 |
DisclosureSEC source: 0000899243-21-036298 · doc4.xml · nonDerivative · entry 2 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,755,222 F3 · shares: Represents (i) 319,871 shares purchased by Thrive VII Growth and (ii) 3,854 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.62 to $18.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,698,612 shares are held directly by Thrive VII Growth and 56,610 shares are held directly by Claremount VII. F3 · price: Represents (i) 319,871 shares purchased by Thrive VII Growth and (ii) 3,854 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.62 to $18.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,698,612 shares are held directly by Thrive VII Growth and 56,610 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 319,871 shares purchased by Thrive VII Growth and (ii) 3,854 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.62 to $18.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,698,612 shares are held directly by Thrive VII Growth and 56,610 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 21:38 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 515,344 | $18.10 | $9,326,180.37 |
DisclosureSEC source: 0000899243-21-036298 · doc4.xml · nonDerivative · entry 1 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,431,497 F1 · shares: Represents (i) 509,209 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 6,135 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.685 to $18.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,378,741 shares are held directly by Thrive VII Growth and 52,756 shares are held directly by Claremount VII. F1 · price: Represents (i) 509,209 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 6,135 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.685 to $18.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,378,741 shares are held directly by Thrive VII Growth and 52,756 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 509,209 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 6,135 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.685 to $18.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,378,741 shares are held directly by Thrive VII Growth and 52,756 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 13, 2021 22:52 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 221,228 | $17.52 | $3,874,830.54 |
DisclosureSEC source: 0000899243-21-035726 · doc4.xml · nonDerivative · entry 5 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,916,153 F6 · shares: 6. Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F6 · price: 6. Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F6 · balance_after: 6. Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 13, 2021 22:52 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 156,324 | $16.84 | $2,632,621.22 |
DisclosureSEC source: 0000899243-21-035726 · doc4.xml · nonDerivative · entry 4 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,694,925 F5 · shares: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F5 · price: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F5 · balance_after: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 28, 2021 22:30 UTC Amendment | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 221,228 | $17.52 | $3,874,830.54 |
DisclosureSEC source: 0000899243-21-038100 · doc4a.xml · nonDerivative · entry 5 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,916,153 F6 · shares: Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F6 · price: Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F6 · balance_after: Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 28, 2021 22:30 UTC Amendment | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 156,324 | $16.84 | $2,632,621.22 |
DisclosureSEC source: 0000899243-21-038100 · doc4a.xml · nonDerivative · entry 4 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,694,925 F5 · shares: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F5 · price: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F5 · balance_after: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 22:52 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 250,000 | $17.50 | $4,375,650.00 |
DisclosureSEC source: 0000899243-21-035726 · doc4.xml · nonDerivative · entry 3 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,538,601 F4 · shares: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F4 · price: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F4 · balance_after: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 10, 2021 Filed Sep 28, 2021 22:30 UTC Amendment | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 250,000 | $17.74 | $4,435,900.00 |
DisclosureSEC source: 0000899243-21-038100 · doc4a.xml · nonDerivative · entry 3 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,538,601 F4 · shares: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F4 · price: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F4 · balance_after: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 22:52 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 263,821 | $17.69 | $4,666,571.38 |
DisclosureSEC source: 0000899243-21-035726 · doc4.xml · nonDerivative · entry 2 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,288,601 F3 · shares: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F3 · price: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 22:52 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 180,891 | $17.23 | $3,117,077.53 |
DisclosureSEC source: 0000899243-21-035726 · doc4.xml · nonDerivative · entry 1 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,024,780 F1 · shares: 1. Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F1 · price: 1. Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F1 · balance_after: 1. Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 28, 2021 22:30 UTC Amendment | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 263,821 | $17.69 | $4,666,571.38 |
DisclosureSEC source: 0000899243-21-038100 · doc4a.xml · nonDerivative · entry 2 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,288,601 F3 · shares: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F3 · price: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 28, 2021 22:30 UTC Amendment | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 180,891 | $17.23 | $3,117,077.53 |
DisclosureSEC source: 0000899243-21-038100 · doc4a.xml · nonDerivative · entry 1 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,024,780 F1 · shares: Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F1 · price: Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 03, 2021 Filed Sep 7, 2021 20:15 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 157,135 | $18.35 | $2,884,165.78 |
DisclosureSEC source: 0000899243-21-035249 · doc4.xml · nonDerivative · entry 3 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,843,889 F4 · shares: Represents (i) 155,264 shares purchased by Thrive VII Growth and (ii) 1,871 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.86 to $18.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,810,033 shares are held directly by Thrive VII Growth and 33,856 shares are held directly by Claremount VII. F4 · price: Represents (i) 155,264 shares purchased by Thrive VII Growth and (ii) 1,871 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.86 to $18.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,810,033 shares are held directly by Thrive VII Growth and 33,856 shares are held directly by Claremount VII. F4 · balance_after: Represents (i) 155,264 shares purchased by Thrive VII Growth and (ii) 1,871 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.86 to $18.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,810,033 shares are held directly by Thrive VII Growth and 33,856 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:15 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 160,385 | $18.35 | $2,942,551.52 |
DisclosureSEC source: 0000899243-21-035249 · doc4.xml · nonDerivative · entry 2 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,686,754 F3 · shares: Represents (i) 158,475 shares purchased by Thrive VII Growth and (ii) 1,910 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $18.01 to $18.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,654,769 shares are held directly by Thrive VII Growth and 31,985 shares are held directly by Claremount VII. F3 · price: Represents (i) 158,475 shares purchased by Thrive VII Growth and (ii) 1,910 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $18.01 to $18.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,654,769 shares are held directly by Thrive VII Growth and 31,985 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 158,475 shares purchased by Thrive VII Growth and (ii) 1,910 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $18.01 to $18.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,654,769 shares are held directly by Thrive VII Growth and 31,985 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:15 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 167,966 | $17.53 | $2,943,805.71 |
DisclosureSEC source: 0000899243-21-035249 · doc4.xml · nonDerivative · entry 1 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,526,369 F1 · shares: Represents (i) 165,967 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,999 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.01 to $18.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,496,294 shares are held directly by Thrive VII Growth and 30,075 shares are held directly by Claremount VII. F1 · price: Represents (i) 165,967 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,999 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.01 to $18.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,496,294 shares are held directly by Thrive VII Growth and 30,075 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 165,967 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,999 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.01 to $18.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,496,294 shares are held directly by Thrive VII Growth and 30,075 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 23:51 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 211,703 | $15.43 | $3,267,170.06 |
DisclosureSEC source: 0000899243-21-034817 · doc4.xml · nonDerivative · entry 4 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,358,403 F5 · shares: Represents (i) 209,183 shares purchased by Thrive VII Growth and (ii) 2,520 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,330,327 shares are held directly by Thrive VII Growth and 28,076 shares are held directly by Claremount VII. F5 · price: Represents (i) 209,183 shares purchased by Thrive VII Growth and (ii) 2,520 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,330,327 shares are held directly by Thrive VII Growth and 28,076 shares are held directly by Claremount VII. F5 · balance_after: Represents (i) 209,183 shares purchased by Thrive VII Growth and (ii) 2,520 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,330,327 shares are held directly by Thrive VII Growth and 28,076 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 23:51 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 93,836 | $14.81 | $1,389,861.30 |
DisclosureSEC source: 0000899243-21-034817 · doc4.xml · nonDerivative · entry 3 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,146,700 F4 · shares: Represents (i) 92,719 shares purchased by Thrive VII Growth and (ii) 1,117 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.115, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,121,144 shares are held directly by Thrive VII Growth and 25,556 shares are held directly by Claremount VII. F4 · price: Represents (i) 92,719 shares purchased by Thrive VII Growth and (ii) 1,117 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.115, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,121,144 shares are held directly by Thrive VII Growth and 25,556 shares are held directly by Claremount VII. F4 · balance_after: Represents (i) 92,719 shares purchased by Thrive VII Growth and (ii) 1,117 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.115, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,121,144 shares are held directly by Thrive VII Growth and 25,556 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:51 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 55,188 | $15.27 | $842,770.43 |
DisclosureSEC source: 0000899243-21-034817 · doc4.xml · nonDerivative · entry 2 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,052,864 F3 · shares: Represents (i) 54,531 shares purchased by Thrive VII Growth and (ii) 657 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,028,425 shares are held directly by Thrive VII Growth and 24,439 shares are held directly by Claremount VII. F3 · price: Represents (i) 54,531 shares purchased by Thrive VII Growth and (ii) 657 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,028,425 shares are held directly by Thrive VII Growth and 24,439 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 54,531 shares purchased by Thrive VII Growth and (ii) 657 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,028,425 shares are held directly by Thrive VII Growth and 24,439 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:51 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 274,697 | $14.68 | $4,033,760.63 |
DisclosureSEC source: 0000899243-21-034817 · doc4.xml · nonDerivative · entry 1 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,997,676 F1 · shares: Represents (i) 271,427 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,270 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,973,894 shares are held directly by Thrive VII Growth and 23,782 shares are held directly by Claremount VII. F1 · price: Represents (i) 271,427 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,270 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,973,894 shares are held directly by Thrive VII Growth and 23,782 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 271,427 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,270 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,973,894 shares are held directly by Thrive VII Growth and 23,782 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 27, 2021 Filed Aug 28, 2021 00:35 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 217,590 | $14.05 | $3,057,988.10 |
DisclosureSEC source: 0000899243-21-034462 · doc4.xml · nonDerivative · entry 3 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,722,979 F4 · shares: Represents (i) 215,000 shares purchased by Thrive VII Growth and (ii) 2,590 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.72 to $14.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. 1,702,467 shares are held directly by Thrive VII Growth and 20,512 shares are held directly by Claremount VII. F4 · price: Represents (i) 215,000 shares purchased by Thrive VII Growth and (ii) 2,590 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.72 to $14.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. 1,702,467 shares are held directly by Thrive VII Growth and 20,512 shares are held directly by Claremount VII. F4 · balance_after: Represents (i) 215,000 shares purchased by Thrive VII Growth and (ii) 2,590 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.72 to $14.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. 1,702,467 shares are held directly by Thrive VII Growth and 20,512 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 26, 2021 Filed Aug 28, 2021 00:35 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 204,811 | $13.74 | $2,814,819.98 |
DisclosureSEC source: 0000899243-21-034462 · doc4.xml · nonDerivative · entry 2 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,505,389 F3 · shares: Represents (i) 202,373 shares purchased by Thrive VII Growth and (ii) 2,438 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.39 to $14.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,487,467 shares are held directly by Thrive VII Growth and 17,922 shares are held directly by Claremount VII. F3 · price: Represents (i) 202,373 shares purchased by Thrive VII Growth and (ii) 2,438 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.39 to $14.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,487,467 shares are held directly by Thrive VII Growth and 17,922 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 202,373 shares purchased by Thrive VII Growth and (ii) 2,438 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.39 to $14.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,487,467 shares are held directly by Thrive VII Growth and 17,922 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 25, 2021 Filed Aug 28, 2021 00:35 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 31,794 | $13.18 | $418,908.21 |
DisclosureSEC source: 0000899243-21-034462 · doc4.xml · nonDerivative · entry 1 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,300,578 F1 · shares: Represents (i) 31,415 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 379 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,285,094 shares are held directly by Thrive VII Growth and 15,484 shares are held directly by Claremount VII. F1 · price: Represents (i) 31,415 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 379 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,285,094 shares are held directly by Thrive VII Growth and 15,484 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 31,415 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 379 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,285,094 shares are held directly by Thrive VII Growth and 15,484 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 24, 2021 Filed Aug 25, 2021 00:44 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 1,074,342 | $12.69 | $13,633,399.98 |
DisclosureSEC source: 0000899243-21-034083 · doc4.xml · nonDerivative · entry 3 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,268,784 F4 · shares: Represents: (i) 1,061,552 shares of Class A common stock purchased by Thrive VII Growth and (ii) 12,790 shares of Class A common stock purchased by Claremount VII. All shares were purchased in accordance with the daily volume and other limitations of Rule 10b-18. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 00:44 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 125,900 | $13.01 | $1,638,009.36 |
DisclosureSEC source: 0000899243-21-034083 · doc4.xml · nonDerivative · entry 2 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 194,442 F3 · shares: Represents: (i) 124,401 shares of Class A common stock purchased by Thrive VII Growth and (ii) 1,499 shares of Class A common stock purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.83 to $13.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations of Rule 10b-18. F3 · price: Represents: (i) 124,401 shares of Class A common stock purchased by Thrive VII Growth and (ii) 1,499 shares of Class A common stock purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.83 to $13.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations of Rule 10b-18. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 20, 2021 Filed Aug 25, 2021 00:44 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 68,542 | $13.41 | $919,196.20 |
DisclosureSEC source: 0000899243-21-034083 · doc4.xml · nonDerivative · entry 1 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 68,542 F1 · shares: Represents: (i) 67,726 shares of Class A common stock purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 816 shares of Class A common stock purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.12 to $13.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations of Rule 10b-18. F1 · price: Represents: (i) 67,726 shares of Class A common stock purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 816 shares of Class A common stock purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.12 to $13.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations of Rule 10b-18. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| May 25, 2021 Filed May 27, 2021 17:06 UTC | Vimeo, Inc. VMEO · Entity 72624 | GrantCommon Stock | 1,549,885 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-020875 · doc4.xml · nonDerivative · entry 5 Thrive Partners V GP, LLC · CIK 0001848079 · Director Thrive Partners VI GP, LLC · CIK 0001848078 · Director Thrive Capital Partners V, L.P. · CIK 0001678271 · Director Claremount V Associates, L.P. · CIK 0001678274 · Director Thrive Capital Partners VI, L.P. · CIK 0001756050 · Director Thrive Capital Partners VI Growth, L.P. · CIK 0001756881 · Director Claremount VI Associates, L.P. · CIK 0001756886 · Director Kushner Joshua · CIK 0001844181 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Thrive Capital Partners VI Growth, L.P. Disclosed balance after: 1,549,885 F1 · kind: Shares acquired in connection with the spin-off of the Issuer from IAC/InterActiveCorp ("IAC") that was completed on May 25, 2021, pursuant to which each share of Vimeo.com, Inc., formerly known as Vimeo, Inc. ("Vimeo"), capital stock issued and outstanding immediately prior to the completion of the spin-off and owned by a non-IAC Vimeo stockholder (other than any dissenting shares) was automatically cancelled and converted into 1.0143 shares of the Issuer's common stock. F1 · price: Shares acquired in connection with the spin-off of the Issuer from IAC/InterActiveCorp ("IAC") that was completed on May 25, 2021, pursuant to which each share of Vimeo.com, Inc., formerly known as Vimeo, Inc. ("Vimeo"), capital stock issued and outstanding immediately prior to the completion of the spin-off and owned by a non-IAC Vimeo stockholder (other than any dissenting shares) was automatically cancelled and converted into 1.0143 shares of the Issuer's common stock. F6 · ownership.nature: Shares held by Thrive Capital Partners VI Growth, L.P. ("Thrive VI Growth" and together with Claremount V, Claremount VI, Thrive V and Thrive VI, the "Thrive Capital Funds"). F7 · ownership.nature: The general partner of each of Thrive V and Claremount V is Thrive Partners V GP, LLC ("Thrive V GP"). The general partner of each of Thrive VI, Thrive VI Growth and Claremount VI is Thrive Partners VI GP, LLC ("Thrive VI GP" and together with Thrive V GP, the "Thrive General Partners"). Joshua Kushner is the sole managing member of each of the Thrive General Partners, and, in his capacity as managing member, may have voting and investment power over the shares held by each of the Thrive Capital Funds. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive Capital Funds except to the extent of their pecuniary interest therein. F8 · ownership.nature: Nabil Mallick, a General Partner at Thrive Capital, has been deputized to represent the reporting persons on the board of directors of the Issuer. By virtue of Mr. Mallick's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the reporting persons may be deemed directors by deputization of the Issuer. Mr. Mallick has filed a separate Section 16 report disclosing securities of the Issuer that he may be deemed to beneficially own for Section 16 purposes. Read SEC document |
| May 25, 2021 Filed May 27, 2021 17:06 UTC | Vimeo, Inc. VMEO · Entity 72624 | GrantCommon Stock | 2,525,739 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-020875 · doc4.xml · nonDerivative · entry 4 Thrive Partners V GP, LLC · CIK 0001848079 · Director Thrive Partners VI GP, LLC · CIK 0001848078 · Director Thrive Capital Partners V, L.P. · CIK 0001678271 · Director Claremount V Associates, L.P. · CIK 0001678274 · Director Thrive Capital Partners VI, L.P. · CIK 0001756050 · Director Thrive Capital Partners VI Growth, L.P. · CIK 0001756881 · Director Claremount VI Associates, L.P. · CIK 0001756886 · Director Kushner Joshua · CIK 0001844181 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Thrive Capital Partners VI, L.P. Disclosed balance after: 2,525,739 F1 · kind: Shares acquired in connection with the spin-off of the Issuer from IAC/InterActiveCorp ("IAC") that was completed on May 25, 2021, pursuant to which each share of Vimeo.com, Inc., formerly known as Vimeo, Inc. ("Vimeo"), capital stock issued and outstanding immediately prior to the completion of the spin-off and owned by a non-IAC Vimeo stockholder (other than any dissenting shares) was automatically cancelled and converted into 1.0143 shares of the Issuer's common stock. F1 · price: Shares acquired in connection with the spin-off of the Issuer from IAC/InterActiveCorp ("IAC") that was completed on May 25, 2021, pursuant to which each share of Vimeo.com, Inc., formerly known as Vimeo, Inc. ("Vimeo"), capital stock issued and outstanding immediately prior to the completion of the spin-off and owned by a non-IAC Vimeo stockholder (other than any dissenting shares) was automatically cancelled and converted into 1.0143 shares of the Issuer's common stock. F5 · ownership.nature: Shares held by Thrive Capital Partners VI, L.P. ("Thrive VI"). F7 · ownership.nature: The general partner of each of Thrive V and Claremount V is Thrive Partners V GP, LLC ("Thrive V GP"). The general partner of each of Thrive VI, Thrive VI Growth and Claremount VI is Thrive Partners VI GP, LLC ("Thrive VI GP" and together with Thrive V GP, the "Thrive General Partners"). Joshua Kushner is the sole managing member of each of the Thrive General Partners, and, in his capacity as managing member, may have voting and investment power over the shares held by each of the Thrive Capital Funds. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive Capital Funds except to the extent of their pecuniary interest therein. F8 · ownership.nature: Nabil Mallick, a General Partner at Thrive Capital, has been deputized to represent the reporting persons on the board of directors of the Issuer. By virtue of Mr. Mallick's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the reporting persons may be deemed directors by deputization of the Issuer. Mr. Mallick has filed a separate Section 16 report disclosing securities of the Issuer that he may be deemed to beneficially own for Section 16 purposes. Read SEC document |
| May 25, 2021 Filed May 27, 2021 17:06 UTC | Vimeo, Inc. VMEO · Entity 72624 | GrantCommon Stock | 1,666,518 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-020875 · doc4.xml · nonDerivative · entry 3 Thrive Partners V GP, LLC · CIK 0001848079 · Director Thrive Partners VI GP, LLC · CIK 0001848078 · Director Thrive Capital Partners V, L.P. · CIK 0001678271 · Director Claremount V Associates, L.P. · CIK 0001678274 · Director Thrive Capital Partners VI, L.P. · CIK 0001756050 · Director Thrive Capital Partners VI Growth, L.P. · CIK 0001756881 · Director Claremount VI Associates, L.P. · CIK 0001756886 · Director Kushner Joshua · CIK 0001844181 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Thrive Capital Partners V, L.P. Disclosed balance after: 1,666,518 F1 · kind: Shares acquired in connection with the spin-off of the Issuer from IAC/InterActiveCorp ("IAC") that was completed on May 25, 2021, pursuant to which each share of Vimeo.com, Inc., formerly known as Vimeo, Inc. ("Vimeo"), capital stock issued and outstanding immediately prior to the completion of the spin-off and owned by a non-IAC Vimeo stockholder (other than any dissenting shares) was automatically cancelled and converted into 1.0143 shares of the Issuer's common stock. F1 · price: Shares acquired in connection with the spin-off of the Issuer from IAC/InterActiveCorp ("IAC") that was completed on May 25, 2021, pursuant to which each share of Vimeo.com, Inc., formerly known as Vimeo, Inc. ("Vimeo"), capital stock issued and outstanding immediately prior to the completion of the spin-off and owned by a non-IAC Vimeo stockholder (other than any dissenting shares) was automatically cancelled and converted into 1.0143 shares of the Issuer's common stock. F4 · ownership.nature: Shares held by Thrive Capital Partners V, L.P. ("Thrive V"). F7 · ownership.nature: The general partner of each of Thrive V and Claremount V is Thrive Partners V GP, LLC ("Thrive V GP"). The general partner of each of Thrive VI, Thrive VI Growth and Claremount VI is Thrive Partners VI GP, LLC ("Thrive VI GP" and together with Thrive V GP, the "Thrive General Partners"). Joshua Kushner is the sole managing member of each of the Thrive General Partners, and, in his capacity as managing member, may have voting and investment power over the shares held by each of the Thrive Capital Funds. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive Capital Funds except to the extent of their pecuniary interest therein. F8 · ownership.nature: Nabil Mallick, a General Partner at Thrive Capital, has been deputized to represent the reporting persons on the board of directors of the Issuer. By virtue of Mr. Mallick's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the reporting persons may be deemed directors by deputization of the Issuer. Mr. Mallick has filed a separate Section 16 report disclosing securities of the Issuer that he may be deemed to beneficially own for Section 16 purposes. Read SEC document |
| May 25, 2021 Filed May 27, 2021 17:06 UTC | Vimeo, Inc. VMEO · Entity 72624 | GrantCommon Stock | 79,902 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-020875 · doc4.xml · nonDerivative · entry 2 Thrive Partners V GP, LLC · CIK 0001848079 · Director Thrive Partners VI GP, LLC · CIK 0001848078 · Director Thrive Capital Partners V, L.P. · CIK 0001678271 · Director Claremount V Associates, L.P. · CIK 0001678274 · Director Thrive Capital Partners VI, L.P. · CIK 0001756050 · Director Thrive Capital Partners VI Growth, L.P. · CIK 0001756881 · Director Claremount VI Associates, L.P. · CIK 0001756886 · Director Kushner Joshua · CIK 0001844181 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Claremount VI Associates, L.P. Disclosed balance after: 79,902 F1 · kind: Shares acquired in connection with the spin-off of the Issuer from IAC/InterActiveCorp ("IAC") that was completed on May 25, 2021, pursuant to which each share of Vimeo.com, Inc., formerly known as Vimeo, Inc. ("Vimeo"), capital stock issued and outstanding immediately prior to the completion of the spin-off and owned by a non-IAC Vimeo stockholder (other than any dissenting shares) was automatically cancelled and converted into 1.0143 shares of the Issuer's common stock. F1 · price: Shares acquired in connection with the spin-off of the Issuer from IAC/InterActiveCorp ("IAC") that was completed on May 25, 2021, pursuant to which each share of Vimeo.com, Inc., formerly known as Vimeo, Inc. ("Vimeo"), capital stock issued and outstanding immediately prior to the completion of the spin-off and owned by a non-IAC Vimeo stockholder (other than any dissenting shares) was automatically cancelled and converted into 1.0143 shares of the Issuer's common stock. F3 · ownership.nature: Shares held by Claremount VI Associates, L.P. ("Claremount VI"). F7 · ownership.nature: The general partner of each of Thrive V and Claremount V is Thrive Partners V GP, LLC ("Thrive V GP"). The general partner of each of Thrive VI, Thrive VI Growth and Claremount VI is Thrive Partners VI GP, LLC ("Thrive VI GP" and together with Thrive V GP, the "Thrive General Partners"). Joshua Kushner is the sole managing member of each of the Thrive General Partners, and, in his capacity as managing member, may have voting and investment power over the shares held by each of the Thrive Capital Funds. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive Capital Funds except to the extent of their pecuniary interest therein. F8 · ownership.nature: Nabil Mallick, a General Partner at Thrive Capital, has been deputized to represent the reporting persons on the board of directors of the Issuer. By virtue of Mr. Mallick's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the reporting persons may be deemed directors by deputization of the Issuer. Mr. Mallick has filed a separate Section 16 report disclosing securities of the Issuer that he may be deemed to beneficially own for Section 16 purposes. Read SEC document |
| May 25, 2021 Filed May 27, 2021 17:06 UTC | Vimeo, Inc. VMEO · Entity 72624 | GrantCommon Stock | 30,809 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-020875 · doc4.xml · nonDerivative · entry 1 Thrive Partners V GP, LLC · CIK 0001848079 · Director Thrive Partners VI GP, LLC · CIK 0001848078 · Director Thrive Capital Partners V, L.P. · CIK 0001678271 · Director Claremount V Associates, L.P. · CIK 0001678274 · Director Thrive Capital Partners VI, L.P. · CIK 0001756050 · Director Thrive Capital Partners VI Growth, L.P. · CIK 0001756881 · Director Claremount VI Associates, L.P. · CIK 0001756886 · Director Kushner Joshua · CIK 0001844181 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Claremount V Associates, L.P. Disclosed balance after: 30,809 F1 · kind: Shares acquired in connection with the spin-off of the Issuer from IAC/InterActiveCorp ("IAC") that was completed on May 25, 2021, pursuant to which each share of Vimeo.com, Inc., formerly known as Vimeo, Inc. ("Vimeo"), capital stock issued and outstanding immediately prior to the completion of the spin-off and owned by a non-IAC Vimeo stockholder (other than any dissenting shares) was automatically cancelled and converted into 1.0143 shares of the Issuer's common stock. F1 · price: Shares acquired in connection with the spin-off of the Issuer from IAC/InterActiveCorp ("IAC") that was completed on May 25, 2021, pursuant to which each share of Vimeo.com, Inc., formerly known as Vimeo, Inc. ("Vimeo"), capital stock issued and outstanding immediately prior to the completion of the spin-off and owned by a non-IAC Vimeo stockholder (other than any dissenting shares) was automatically cancelled and converted into 1.0143 shares of the Issuer's common stock. F2 · ownership.nature: Shares held by Claremount V Associates, L.P. ("Claremount V"). F7 · ownership.nature: The general partner of each of Thrive V and Claremount V is Thrive Partners V GP, LLC ("Thrive V GP"). The general partner of each of Thrive VI, Thrive VI Growth and Claremount VI is Thrive Partners VI GP, LLC ("Thrive VI GP" and together with Thrive V GP, the "Thrive General Partners"). Joshua Kushner is the sole managing member of each of the Thrive General Partners, and, in his capacity as managing member, may have voting and investment power over the shares held by each of the Thrive Capital Funds. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive Capital Funds except to the extent of their pecuniary interest therein. F8 · ownership.nature: Nabil Mallick, a General Partner at Thrive Capital, has been deputized to represent the reporting persons on the board of directors of the Issuer. By virtue of Mr. Mallick's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the reporting persons may be deemed directors by deputization of the Issuer. Mr. Mallick has filed a separate Section 16 report disclosing securities of the Issuer that he may be deemed to beneficially own for Section 16 purposes. Read SEC document |
| March 05, 2021 Filed Mar 5, 2021 23:29 UTC | Oscar Health, Inc. OSCR · Entity 3582 | GrantPerformance Restricted Stock Units · Derivative | 2,114,926 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-010192 · doc4.xml · derivative · entry 1 Kushner Joshua · CIK 0001844181 · Director · Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,114,926 Underlying: Class A Common Stock · 2,114,926 shares Expires 2028-03-05 F1 · derivative.exercise_price: Each performance restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The performance restricted stock units vest upon the Issuer's common stock achieving certain specified price per share targets ranging from $90 to $270 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.